Timothy D. Lyon, MD, outlines trial of in-home intravesical therapy for bladder cancer

In this video, Timothy D. Lyon, MD, gives an overview of his Desai Sethi Urology Institute Urology on the Beach presentation “In-Home Therapy for Bladder Cancer.” Lyon is an associate professor of urology and Urology Residency Program Director at Mayo Clinic in Jacksonville, Florida.

Transcription:

At Mayo Clinic, we think that delivering intravesical therapy for non muscle invasive bladder cancer in patients' homes has the potential to reduce treatment burden, improve the patient experience, as well as increase access to care. And we're currently conducting a clinical trial called the INVITE trial for in-home intravesical therapy to test that hypothesis. The background of this study, as anyone who treats bladder cancer knows, receiving intravesical therapy for non muscle invasive bladder cancer can be an incredibly burdensome care process, with frequent weekly visits for treatments, periodic cystoscopic surveillance. In fact, if you were to precisely follow the SWOG treatment protocol for the first year of induction and maintenance BCG, that's 19 visits in the first year to the urologist, not to mention any other unscheduled visits, urinalyses, urine cultures, and this is in a patient population that's generally older and has multiple comorbidities, so they've got other doctors to see. So really, it's a lot that we're asking of our patients, and some of the survey data that we've done with bladder cancer survivors has indicated that helping bring the treatments to where they are and delivering it in their homes may help reduce the treatment burden. So that's what we're excited about doing. At present, we're performing the INVITE trial, as I mentioned before, which is enrolling patients who are beginning induction intravesical therapy with one of a few eligible regimens: BCG, gemcitabine, mitomycin, or gemcitabine/docetaxel. They come to the office and receive the first dose in the clinic to make sure that they can tolerate it, and then doses 2 through 6 are delivered in their homes by a network of contracted home care nursing providers. Co-primary end points of this study are safety, so frequency, nature and severity of adverse events, as well as feasibility, which we're defining as the ability to deliver at least 5 of 6 planned treatments over a 12-week period of time. Key secondary outcomes include patient satisfaction, health-related quality life, etc. So we're very excited to be generating some data to test this hypothesis.

This transcription was AI generated and edited by human editors for clarity.